Health Condition 1: B081- Molluscum contagiosum
Conditions
Interventions
Intervention1: MMR vaccine: Injection of 0.3 ml MMR vaccine will be administered intralesionally into large lesion of molluscum contagiosum among participants without pre-sensitization for every thre
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients aged > 12 years, irrespective of sex. 2. Immunocompetent 3. Having more than 10 MC lesions 4. Consenting patients.
Exclusion criteria
Exclusion criteria: 1. Participants those who had history of any life-threatening allergies 2. Pregnant and lactating mothers 3. Severe organ dysfunction/ immunosuppression. 4. Family history of severe immune dysfunction 5. Fever, or any signs of local or systemic infection. 6. Patients with tuberculosis, HIV, Hepatitis B and Hepatitis C 7. Those who cannot provide consent for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients showing complete clearance of molluscum contagiosum lesions at 12 weeks follow up in both arms.Timepoint: At the end of 12 weeks in both arms (i.e., at the end of 6 weeks after 3rd injection received). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proportion of patients showing at least 50% reduction in lesion count at 12 weeks follow up in both arms. 2. To evaluate the safety profile and documentation of adverse effects of intralesional MMR vaccine in MC patients Timepoint: At the end of 12 weeks in both arms(i.e., at the end of 6 weeks after receiving 3rd injection) | — |
Countries
India
Contacts
Public ContactVinay Keshavamurthy
Post graduate institute of medical education and research
Outcome results
None listed